Lawrence H. Einhorn

Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes

Towfik Sebai, Rebecca Hassoun, Sandra Althouse, Jennifer King et autres

us (code pays fourni par la source)

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors

Rebecca Hassoun, Reuben Ben‐David, John P. Sfakianos, George Laliotis et autres

PURPOSE Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial proportion of patients are normal or falsely elevated. We evaluated circulating tumor DNA …

us (code pays fourni par la source)

Impact of Population Pharmacogenomics on Cisplatin‐Induced Neurotoxicities in Testicular Cancer Survivors

Swetha Nakshatri, Paul C. Dinh, Lawrence H. Einhorn, Darren R. Feldman et autres

ABSTRACT Background Cisplatin is a commonly used chemotherapeutic across numerous cancer types that can cause neurotoxicities in patients, including peripheral sensory neuropathy, tinnitus, hearing loss, and vertigo. Objective We aimed to evaluate, for the first time, how genetic ancestry impacts cisplatin‐induced neurotoxicities …

us, ca, gb (code pays fourni par la source)

Clinical characteristics and outcomes of metastatic germ cell tumors with highly elevated human chorionic gonadotropin levels.

Noah Richardson, Rebecca Hassoun, Sandra K. Althouse, Tareq Salous et autres

e17018 Background: Serum human chorionic gonadotropin (hCG) levels greater than 50,000 in the pretreatment assessment of metastatic germ cell tumors (GCT) indicate poor-risk disease with serial levels during and after first-line chemotherapy incorporated into the response assessment. We aimed to describe the …

us (code pays fourni par la source)

TROP-2 expression in germ cell tumors (GCT).

Noah Richardson, Tareq Salous, Jennifer King, Nasser H. Hanna et autres

5031 Background: Trophoblast cell surface antigen 2 (TROP-2) is a tumor associated antigen overexpressed in several malignancies including breast and urothelial cancer. The TROP-2 antibody-drug conjugate (ADC) Sacituzumab govitecan is approved for treatment of metastatic breast cancer. The expression of TROP-2 in …

us (code pays fourni par la source)

Initiation of high dose chemotherapy at rising tumor markers compared with radiographic progression in patients with relapsed germ-cell tumors (GCT).

Rebecca Hassoun, Rafat Abonour, Sandra K. Althouse, Tareq Salous et autres

5033 Background: Patients with GCT who relapse after first-line therapy can be cured with salvage high-dose chemotherapy (HDCT). We evaluate the outcomes of patients who received HDCT based on tumor maker rise only compared to radiographic progression only or both. Methods: The …

us (code pays fourni par la source)

Key Updates in Testicular Cancer: Optimizing Survivorship and Survival

Aditya Bagrodia, Hege Sagstuen Haugnes, Ragnhild Hellesnes, Mai Dabbas et autres

Testicular cancer is a rare but highly curable malignancy, predominantly affecting young men. Advances in multimodal therapy, including cisplatin-based chemotherapy, radiotherapy, and surgical interventions, have resulted in excellent cancer-specific survival. However, with improved survival rates, long-term health consequences and survivorship issues have …

us, no, ca (code pays fourni par la source)

Abstract 4357: Disparities in neurotoxicities in cisplatin-treated cancer patients: a population pharmacogenomics approach

Swetha Nakshatri, Paul C. Dinh, Darren R. Feldman, Robert J. Hamilton et autres

Abstract Background: Disparities in peripheral sensory neuropathy (PSN) have been studied in taxane-treated breast cancer and vincristine-treated leukemia survivors, but not addressed in cisplatin. Both platinum compounds and environmental heavy metals are associated with vascular toxicity, and there is genetic variation in …

us, ca, gb (code pays fourni par la source)

Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial

Brian Hu, Muhannad Alsyouf, Ala’a Farkouh, Clint Cary et autres

PURPOSE: Recent clinical trials on primary retroperitoneal lymph node dissection (RPLND) for testicular seminoma highlight inaccuracies in conventional imaging for lymph node staging. Limited data exist on the accuracy of positron emission tomography (PET) in patients with chemotherapy-naïve testicular seminoma. We evaluated …

us, ca (code pays fourni par la source)

Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.

Ahmed Bilal Khalid, Sandra K. Althouse, Rebecca Hassoun, Tareq Salous et autres

630 Background: For patients (pts) with stage 1 seminomatous germ cell tumor (SGCT) on active surveillance (AS), front-line therapy depends on the location and extent of relapse. We describe the characteristics and management of pts on AS with stage I SGCT with …

us (code pays fourni par la source)

Management of relapsed primary retroperitoneal (RP) germ-cell tumor (GCT) after front-line chemotherapy.

Rebecca Hassoun, Sandra K. Althouse, Tareq Salous, Nasser H. Hanna et autres

637 Background: Primary RP GCT represents a rare subset of extragonadal GCTs. While front-line therapy remains similar to gonadal GCT, there is limited data on management of relapsed disease for these patients (pts). Here, we describe management and outcomes of pts with …

us (code pays fourni par la source)

Stage II embryonal predominant NSGCT: Minimizing treatment burden.

Jiping Zeng, Parth Thakker, Timothy A. Masterson, Tareq Salous et autres

634 Background: Embryonal carcinoma predominance (ECP) in the orchiectomy specimen is linked to a higher risk of retroperitoneal and systemic relapse. Both chemotherapy and primary retroperitoneal lymph node dissection (RPLND) are recommended options for stage II disease, but the approach that minimizes …

us (code pays fourni par la source)